½ÃÀ庸°í¼­
»óǰÄÚµå
1673044

ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå : ¿ä¹ýº°, Stageº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°

Metastatic Melanoma Therapeutics Market, By Therapy, By Stages, By End User, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2025³â 80¾ï ´Þ·¯, 2032³â¿¡´Â 180¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 12.3%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 80¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 12.30% 2032³â °¡Ä¡ ¿¹Ãø 180¾ï 2,000¸¸ ´Þ·¯
±×¸². ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²(%), Áö¿ªº° 2025³â
Metastatic Melanoma Therapeutics Market-IMG1

ÀüÀ̼º Èæ»öÁ¾Àº »ý¸íÀ» À§ÇùÇÏ´Â ÇǺξÏÀÇ ÀÏÁ¾À¸·Î Èæ»öÁ¾ ÇǺξÏÀÌ ½ÅüÀÇ ´Ù¸¥ Àå±â·Î ÀüÀÌµÇ¾î ¹ß»ýÇÕ´Ï´Ù. ÃÖ±Ù ¿¬±¸¿¡ µû¸£¸é, 2020³â Àü ¼¼°èÀûÀ¸·Î 20¸¸ ¸í ÀÌ»óÀÇ ½Å±Ô Èæ»öÁ¾ ȯÀÚ°¡ º¸°íµÇ¾î °¡Àå ÈçÇÑ ¾Ï Áß Çϳª°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î Èæ»öÁ¾ ¹ßº´·ü Áõ°¡¿Í ÀüÀ̼º Èæ»öÁ¾°ú °ü·ÃµÈ ³ôÀº »ç¸Á·ü·Î ÀÎÇØ ÀÌ ÀûÀÀÁõ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á Á¢±Ù¹ý¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¶»ç°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù ¸î °¡Áö Ç¥ÀûÄ¡·áÁ¦¿Í ¸é¿ªÄ¡·áÁ¦°¡ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦·Î ½ÂÀεǾú½À´Ï´Ù. ±×·¯³ª ÀÓ»ó °á°ú¸¦ °³¼±ÇÏ°í º¸´Ù È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¹ÌÃæÁ· ¼ö¿ä´Â ¿©ÀüÈ÷ ³ô½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀº Àڿܼ± ³ëÃâ Áõ°¡·Î ÀÎÇÑ Àü ¼¼°è Èæ»öÁ¾ ¹ßº´·ü Áõ°¡¿Í Èæ»öÁ¾¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î Ç¥Àû Ä¡·áÁ¦¿Í ¸é¿ª°ü¹®¾ïÁ¦Á¦°¡ Áö¼ÓÀûÀ¸·Î ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹ÞÀ½¿¡ µû¶ó ½ÃÀå ¹üÀ§°¡ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÷´Ü Ç¥ÀûÄ¡·áÁ¦ ¹× ¸é¿ªÄ¡·áÁ¦¿Í °ü·ÃµÈ °íºñ¿ëÀº ±¤¹üÀ§ÇÑ Ã¤Åÿ¡ ¿µÇâÀ» ¹ÌÄ¡´Â Å« °úÁ¦·Î ³²¾ÆÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÝÀÀ·ü°ú ³»¼º ¹ß»ýÀ¸·Î ÀÎÇØ ±âÁ¸ Ä¡·á¹ýÀÇ Àå±âÀûÀÎ »ç¿ë¿¡´Â ÇѰ谡 ÀÖ½À´Ï´Ù. º´¿ë¿ä¹ý°ú °°Àº Çõ½ÅÀûÀÎ Ä¡·á Àü·«ÀÇ °³¹ßÀº ÇöÀçÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÇØ°áÇϰí ÇâÈÄ ¸î ³âµ¿¾È ½ÃÀå ¼ºÀåÀ» Áõ°¡½Ãų ¼ö ÀÖ´Â Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í CAGRÀ» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
  • ¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
  • ¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ±âÁØÀ¸·Î Á¤¸®ÇÏ¿© ¼ö·ÏÇÏ¿´½À´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
  • ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
  • PEST ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå, ¿ä¹ýº°, 2020³â-2032³â(10¾ï ´Þ·¯)

  • È­Çпä¹ý
  • ¸é¿ªÄ¡·á
  • Ç¥ÀûÄ¡·á
  • ¹æ»ç¼± ¿ä¹ý

Á¦6Àå ¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå, Stageº°, 2020³â-2032³â(10¾ï ´Þ·¯)

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

Á¦7Àå ¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â(10¾ï ´Þ·¯)

  • º´¿ø
  • ¾Ï¼¾ÅÍ
  • ȨÄɾî
  • Àü¹® Ŭ¸®´Ð
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ÀüÀ̼º Èæ»öÁ¾ Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°, 2020³â-2032³â(10¾ï ´Þ·¯)

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Johnson &Johnson Private Limited
    • Sun Pharmaceutical Industries Limited
    • Sanofi SA
    • Bayer AG
    • Lilly
    • Merck &Co., Inc.
    • GSK plc
    • Novartis AG
    • AbbVie Inc.
    • Bausch Health Companies Inc.
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc.
    • AstraZeneca PLC
    • Daiichi Sankyo Company, Limited

Á¦10Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

  • ±âȸ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • Coherent Opportunity Map

Á¦11Àå Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
LSH 25.04.14

Global Metastatic Melanoma Therapeutics Market is estimated to be valued at USD 8.00 Bn in 2025 and is expected to reach USD 18.02 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 8.00 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 12.30% 2032 Value Projection: USD 18.02 Bn
Figure. Metastatic Melanoma Therapeutics Market Share (%), By Region 2025
Metastatic Melanoma Therapeutics Market - IMG1

Metastatic melanoma is a life-threatening form of skin cancer that occurs due to the spread of melanoma skin cancer to other organs of the body. According to recent studies, over 200,000 new cases of melanoma were reported globally in 2020, making it one of the most common types of cancer. The rising global incidence of melanoma coupled with the high mortality rate associated with metastatic melanoma has driven extensive research into new therapeutic approaches for this indication. Several targeted therapies and immunotherapy drugs have been approved in recent years for the treatment of metastatic melanoma. However, there remains a significant unmet need for more effective and safer treatment options with improved clinical outcomes.

Market Dynamics:

The global metastatic melanoma therapeutics market is driven by the increasing incidence of melanoma worldwide due to rising UV radiation exposure and growing awareness about the disease. Moreover, continual approvals of novel targeted therapies and immune checkpoint inhibitors by regulatory agencies are further expanding the market scope. However, high costs associated with advanced targeted drugs and immunotherapy treatments remain a major challenge affecting broader adoption. Additionally, limitations in terms of response rate and emergence of resistance pose limitations on the long-term usage of existing therapies. The development of innovative treatment strategies, such as combination therapies, holds significant potential to address the current unmet needs and augment the market growth in the coming years.

Key Features of the Study:

  • This report provides in-depth analysis of the global metastatic melanoma therapeutics market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global metastatic melanoma therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Amgen, Bristol-Myers Squibb, Roche, Novartis, Merck, and Eli Lilly
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global metastatic melanoma therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global metastatic melanoma therapeutics market

Detailed Segmentation-

  • By Therapy
    • Chemotherapy
    • Immunotherapy
    • Targeted therapy
    • Radiation therapy
  • By Stages
    • Stage 0
    • Stage I
    • Stage II
    • Stage III
    • Stage IV
  • By End User
    • Hospitals
    • Cancer Centers
    • Homecare
    • Specialty Clinics
    • Others
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Johnson & Johnson Private Limited
    • Sun Pharmaceutical Industries Limited
    • Sanofi S.A.
    • Bayer AG
    • Lilly
    • Merck & Co., Inc.
    • GSK plc
    • Novartis AG
    • AbbVie Inc.
    • Bausch Health Companies Inc.
    • Hoffmann-La Roche Ltd
    • Amgen Inc.
    • AstraZeneca PLC
    • Daiichi Sankyo Company, Limited

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapy
    • Market Snapshot, By Stages
    • Market Snapshot, By End User
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Metastatic Melanoma Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Metastatic Melanoma Therapeutics Market, By Therapy, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Chemotherapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Immunotherapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Targeted therapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Radiation therapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Metastatic Melanoma Therapeutics Market, By Stages, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Stage 0
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Stage I
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Stage II
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Stage III
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Stage IV
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Metastatic Melanoma Therapeutics Market, By End User, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cancer Centers
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Homecare
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Clinics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Metastatic Melanoma Therapeutics Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Stages, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Johnson & Johnson Private Limited
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sun Pharmaceutical Industries Limited
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sanofi S.A.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bayer AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Lilly
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GSK plc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AbbVie Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bausch Health Companies Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • F. Hoffmann-La Roche Ltd
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Amgen Inc.
    • AstraZeneca PLC
    • Daiichi Sankyo Company, Limited

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦